Leap Therapeutics, Inc. (LPTX) has been beaten down lately with too much selling pressure. While the stock has lost 28.9% over the past four weeks, there is light at the end of the tunnel as it is now ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Leap Therapeutics, Inc. (NASDAQ: LPTX) and Flame Biosciences, Inc. is fair to Leap ...

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Leap Therapeutics (LPTX – Research Report) today and set a price target of $7.00. The company’s shares closed yesterday at ...

LEAP THERAPEUTICS ($LPTX) is expected to release its quarterly earnings data on Monday, March 17th after market close, per Finnhub. Analysts are expecting revenue of ...

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in ...

The Cambridge, Massachusetts-based biotechnology company announced $58.88 million in cash commitments for a private investment in public equity offering led by Winklevoss Capital. According to an Oct.

In this article we will check out the progression of hedge fund sentiment towards LEAP THERAPEUTICS, INC. (NASDAQ:LPTX) and determine whether it is a good investment right now. We at Insider Monkey ...